Table 4 Comparison of BMI, HbA1c, FPG, Basal and Bolus Insulin Doses at Baseline and 26 weeks after IDeg Treatment among patients who were previously on insulin Glargine (Group A) vs. previously insulin naïve (Group B)
Characteristics | Baseline | 26 weeks |
|---|---|---|
BMI (SDS) | ||
Group A (n = 20) | −0.11 ± 0.76 | 0.04 ± 0.73 |
Group B (n = 10) | 0.38 ± 1.31 | 0.37 ± 1.19 |
HbA1c (%) | ||
Group A (n = 20) | 8.50 ± 0.65 | 8.16 ± 0.67* |
Group B (n = 10) | 11.94 ± 1.78 | 9.47 ± 2.52* |
FPG (mg/dL) | ||
Group A (n = 20) | 135.80 ± 19.05 | 104.50 ± 20.69* |
Group B (n = 10) | 199.20 ± 45.18 | 119.10 ± 39.50* |
Insulin dose (U/kg of body weight/day) | ||
Basal insulin | ||
Group A (n = 20) | 0.45 ± 0.15 | 0.47 ± 0.14 |
Group B (n = 10) | 0.36 ± 0.05 | 0.43 ± 0.13 |
Bolus insulin | ||
Group A (n = 20) | 0.46 ± 0.20 | 0.32 ± 0.10* |
Group B (n = 10) | 0.54 ± 0.22 | 0.41 ± 0.21 |
Total insulin | ||
Group A (n = 20) | 0.91 ± 0.33 | 0.79 ± 0.21* |
Group B (n = 10) | 0.91 ± 0.24 | 0.84 ± 0.31 |